Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended Thromboprophylaxis After Liver Surgery

J Thromb Haemost; ePub 2017 Sep 27; Kim, et al

People who underwent oncologic liver surgery appeared to benefit from extended pharmacologic thromboprophylaxis, according to a study involving 124 individuals. Participants underwent liver resection between 2013 and 2015 and received extended pharmacologic thromboprophylaxis that included venous thromboembolism prophylaxis intraoperatively and daily during hospitalization. Most also received enoxaparin for 2 weeks or 1 month after discharge, depending on the type of surgery they had. Among the results:

  • Intraoperative transfusion rate was 6%; post-op and overall transfusion rates were 8% and 11%, respectively.
  • There were no postoperative symptomatic deep vein thrombosis or pulmonary embolic events during 90 days of follow-up.
  • No pulmonary emboli or other thoracic, splanchnic, or ileofemoral vein thromboses were seen in those with available CT scans.
  • 2 patients had minor bleeding events until enoxaparin was discontinued.
  • 6% experienced severe complications.
  • There were no deaths at 90 days.

Citation:

Kim B, Day R, Davis C, et al. Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. [Published online ahead of print September 27, 2017]. J Thromb Haemost. doi:10.1111/jth.13814.

This Week's Must Reads

Cochrane on Use of TPO-RAs to Prevent, Treat CIT, Cochrane; 2017 Nov 27; Zhang, Chuai, Nie, et al

Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

Conditioning Regimens After HCT Compared in ALL, Biol Blood Marrow Transplant; ePub 2017 Nov 29; Kebriaei, et al

Acute Kidney Injury in Young Allo-HCT Recipients, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Koh, et al

Moral Distress in HCT Professionals Evaluated, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Neumann, et al

Must Reads in Bleeding Disorders

Cochrane on Use of TPO-RAs to Prevent, Treat CIT, Cochrane; 2017 Nov 27; Zhang, Chuai, Nie, et al

Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

Which SCD Vaso-Occlusive Episode Protocol Is Best?, Am J Hematol; ePub 2017 Nov 10; Tanabe, et al

Custom Assay Screens for von Willebrand Disease, J Thromb Haemost; ePub 2017 Nov 23; Lehman, et al

Cochrane on EPO Therapy in Low Birth Weight Infants, Cochrane; 2017 Nov 16; Ohlsson, Aher